drugset / Trial / NCT01355289
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
Timeline
- Start
- 2011-11
- Primary completion
- 2014-02
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 10 mg | Oral |
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |
| Subject | Avatrombopag | Small molecule | 30 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |
| Background | Telaprevir | Small molecule | — | — |